COSMOS Pharmaceutical (3349) Q1 2026 earnings summary

Executive summary

• Net sales for the three months ended August 31, 2025, rose 4.0% year-over-year to ¥272,394 million, with operating profit up 0.6% to ¥11,645 million and profit attributable to owners of parent up 0.3% to ¥8,171 million.

• Store network expanded by 12 new stores and 1 closure, totaling 1,620 stores at period end.

• The business environment was challenging due to weak consumer sentiment and rising prices, prompting a focus on cost efficiency and low-price, high-quality offerings.

Financial highlights

• Gross profit increased to ¥57,174 million from ¥54,562 million year-over-year.

• Ordinary profit slightly decreased by 0.9% to ¥12,188 million.

• Basic earnings per share were ¥103.10, reflecting a 2-for-1 stock split.

• Comprehensive income was ¥8,167 million, up 0.3% year-over-year.

Outlook and guidance

• Full-year forecast for fiscal year ending May 31, 2026: net sales ¥1,057,000 million (+4.5%), operating profit ¥40,500 million (+0.2%), profit attributable to owners of parent ¥31,000 million (+0.1%).

• No change to previously announced financial results forecast.

• Annual dividend forecast raised to ¥75.00 per share.